Chapters

Transcript

Video

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor
Department of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands